These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 15146376)

  • 1. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].
    Doehn C; Merseburger AS; Jocham D; Kuczyk MA
    Urologe A; 2007 Oct; 46(10):1371-2, 1374, 1376-8. PubMed ID: 17805507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
    Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
    Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy in metastatic cancer of the kidney].
    Escudier B
    Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current aspects in the therapy of renal cell cancer].
    Heynemann H
    Praxis (Bern 1994); 2008 Apr; 97(8):427-30. PubMed ID: 18551912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
    Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
    Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokine therapy of metastatic renal cell carcinoma].
    Otto T; Goepel M; Luboldt HJ; Rübben H
    Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines and cytotoxic agents in renal cell carcinoma: a review.
    Stahl M; Wilke HJ; Seeber S; Schmoll HJ
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):70-9. PubMed ID: 1553577
    [No Abstract]   [Full Text] [Related]  

  • 20. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
    Herrmann E; Brinkmann OA; Bode ME; Bierer S; Köpke T; Bögemann M; Hertle L; Wülfing C
    Eur Urol; 2007 Jun; 51(6):1625-31; discussion 1631-2. PubMed ID: 17113215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.